MacroGenics, Inc.
MGNX
NASDAQ·Healthcare·Biotechnology·Mkt cap $279.7M
$4.40
▲ +3.53%
P/E
-20.00
Mkt Cap
$279.7M
52-Wk Range
$1.29–$5.08
52-Week Range
$1.29 - $5.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 150.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary DART bispecific antibody technology platform enabling multi-targeted immune engagement
- FDA-approved commercial product (MARGENZA) generating revenue and validating platform
- Strategic partnerships with Janssen, Incyte, and Zai Lab providing funding and market access
- Deep pipeline of 8+ clinical-stage candidates addressing large oncology and autoimmune markets
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
MARGENZA commercialization and market expansion in HER2-positive breast cancer
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+12.5% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MGNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of $0.31 vs -$0.08 consensus (+498.1% surprise). Revenue of $32.8M vs $59.1M expected (-44.5%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+498.1%
Revenue trend · last 8Q
—
—
+45%
+106%
-34%
+133%
+57%
+48%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$110.7M
$17.7M
$13.2M
$22.2M
$72.8M
$41.2M
$20.8M
$32.8M
Margins · last 8Q
Gross
0.0%
Operating
-42.2%
Profit
59.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · $6.00 · Apr 20, 2026
vs Industry
How MGNX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.